Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.59% | -9.95% | 22.15% | 48.25% | -50.89% |
| Total Depreciation and Amortization | 5.88% | 7.58% | 8.64% | 4.71% | 4.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 198.26% | -57.36% | -90.31% | 695.87% | 626.63% |
| Change in Net Operating Assets | -420.13% | 209.84% | 88.91% | -1,961.68% | -141.49% |
| Cash from Operations | -18.12% | 15.97% | -5.63% | 66.18% | -68.87% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 151.36% | -274.29% | 60.76% | -72.65% | 696.25% |
| Cash from Investing | 151.41% | -274.11% | 61.22% | -72.73% | 718.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.96% | 24,356.04% | -56.31% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 0.00% | 0.00% | 33.04% |
| Cash from Financing | -97.33% | 302,332.61% | -94.12% | 248.95% | -523.39% |
| Foreign Exchange rate Adjustments | 156.85% | -312.80% | 515.60% | 62.80% | -123.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.81% | 437.30% | 137.57% | 26.57% | 82.66% |